<DOC>
	<DOCNO>NCT02244333</DOCNO>
	<brief_summary>Study ass efficacy , tolerability safety parameter one month ALNA® - treatment switch Terazosin-treatment</brief_summary>
	<brief_title>Efficacy , Tolerability Safety ALNA® Patients With Benign Prostatic Syndrome ( BPS )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Suffering BPS symptom Preceding treat Terazosin least one month IPSS sum score &gt; = 8 point prior treatment start ALNA® complaint due BP reduction Terazosin Indication switch treatment ALNA® accord Summary Product Characteristics ( SPC ) minimum period one month Patients fulfil one general specific contraindication list ALNA® SPC , particularly patient know hypersensitivity tamsulosin hydrochloride ingredient product , orthostatic dysregulation severe liver insufficiency could include Post Marketing Surveillance ( PMS ) study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>